Table 1

Patient characteristics

Characteristics
Evaluable patients190
Age [median (range)], years61 (22–89)
Follow-upa [median (range)], months25 (0.7–126)
FIGO stage, n (%)
 IA5 (2%)
 IB1 (1%)
 IC4 (2%)
 IIB4 (2%)
 IIC7 (4%)
 IIIA1 (1%)
 IIIB4 (2%)
 IIIC149 (78%)
 IV15 (8%)
Histology, n (%)
 Papillary serous143 (79%)
 Clear cell8 (4%)
 Endometroid8 (4%)
 Mucinous4 (2%)
 Undifferentiated6 (4%)
 Others (transitional, mixed, carcinosarcoma)13 (7%)
Grade, n (%)
 111 (6%)
 210 (5%)
 3169 (88%)
Response to frontline therapy, n (%)
 Complete response97 (51%)
 Partial response81 (42%)
 Progression3 (2%)
 Unknown9 (5%)
Recurrences,b n (%)
 Recurrence/persistent disease138 (78%)
Current status, n (%)
 Alive, NEDc53 (28%)
 Alive with disease59 (31%)
 Dead of disease74 (39%)
 Dead from other causes3 (2%)
CT antigen status (RT-PCR and/or IHC), n (%)
 NY-ESO-1 positive82/190 (43%)
 LAGE-1 positive (RT-PCR only)22/107 (21%)
 NY-ESO-1 and/or LAGE-1 positive42/107 (40%)
Humoral immune response, n (%)
 NY-ESO-110/37 (30%)
 LAGE-13/6 (50%)
  • a Median survival for all patients: 55 (CI, 37.6–71.41) months.

  • b Median disease-free survival (excluding patients with persistent disease): 33 (CI, 23–42) months.

  • c NED, no evidence of disease.